

## Recombinant Human Interleukin-6 (IL-6)

Publication Number MAN0003501

Revision Date 03 May 2011

| Catalog Number:                   | PHC0064  | PHC0065  | PHC0066 | PHC0061 | PHC0063 |  |
|-----------------------------------|--|--|---------|---------|---------|--|
| Quantity:                         | 5 µg   | 10 µg  | 25 µg   | 100 µg  | 1 mg    |  |
| Lot Number:                       | See product label.   |  |         |         |         |  |
| Molecular Weight:                 | 21.3 kDa   |  |         |         |         |  |
| Purity:                           | >95% as determined by SDS-PAGE analysis.   |  |         |         |         |  |
| Amino Acid<br>Sequence:           | PVPPGEDSKD VAAPHRQPLT SSERIDKQIR YILDGISALR KETCNKSNMC ESSKEALAEN NLNLPKMAEK<br>DGCFQSGFNE ETCLVKIITG LLEFEVYLEY LQNRFESSEE QARAVQMSTK VLIQFLQKKA KNLDAITTPD<br>PTTNASLLTK LQAQNQWLQD MTTHLILRSF KEFLQSSLRA LRQM   |  |         |         |         |  |
| Biological Activity:              | $ED_{50}$ range = 0.008–0.02 ng/mL (Specific Activity: $1.25 \times 10^8$ – $5.0 \times 10^7$ units/mg), determined by the dose dependent proliferation of mouse B9 cells. The optimal concentration for each specific application should be determined by an initial dose-response assay.   |  |         |         |         |  |
| Formulation:                      | Lyophilized, carrier free.   |  |         |         |         |  |
| Sterility:                        | Filtered prior to lyophilization through a 0.22 micron sterile filter.   |  |         |         |         |  |
| Endotoxin:                        | <0.1 ng/µg   |  |         |         |         |  |
| Production:                       | Recombinant human IL-6 is produced in <i>E. coli</i> and purified via sequential chromatography.   |  |         |         |         |  |
| Reconstitution<br>Recommendation: | Lyophilized hIL–6 should be reconstituted in 100 mM acetic acid to a concentration of 0.1–1.0 mg/mL to regain full activity. Stock solutions should be apportioned into working aliquots and stored at $\leq$ -20°C. Further dilutions should be made in low endotoxin medium or buffered solution with FBS or tissue culture grade BSA.   |  |         |         |         |  |
| Suggested<br>Working Dilutions:   | The optimal concentration should be determined for each specific application.  |  |         |         |         |  |
| Storage:                          | Lyophilized hIL–6 should be stored at 2°C to 8°C, preferably desiccated. Store reconstituted hIL–6 at ≤–20°C (not in a frost-free freezer). Keep freeze-thaw cycles to a minimum.  |  |         |         |         |  |
| Expiration Date:                  | Expires one year from date of receipt when stored as instructed.   |  |         |         |         |  |
| References:                       | pp 145–168.<br>Agrawal, A., H. Cha-I<br>requires synergis<br>J. Immunol. 166(4<br>Craig, R., A.M. Larkir<br>mitogen-activate<br>and release: evid<br>J.Biol. Chem. 275<br>Cha-Molstad, H., A. A<br>cytokine-induced<br>Dao, M., N. Taylor, ar<br>coupled with tran<br>transduction of p<br>Dao, M.A., J. Hwa, an<br>cycle modulation<br>Kahlert, H., E. Grage-<br>Influence of the t | kin, A.M. Mingo, D.J. Thuerauf, C. Andrews, P.M. McDonough, and C.C. Glembotski (2000) p38<br>ated protein kinase and nuclear factor- $\kappa$ B collaborate to induce interleukin-6 gene expression<br>ridence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system.<br>275(31):23814–23824.<br>A. Agrawal, D. Zhang, D. Samols, and I. Kushner (2000) The rel family member p50 mediates<br>ceed C-reactive protein expression by a novel mechanism. J. Immunol. 165:4592–4597.<br>, and J. Nolta (1998) Reduction in levels of the cyclin-dependent kinase inhibitor p27kip-1<br>transforming growth factor $\beta$ neutralization induces cell-cycle entry and increases retroviral<br>of primitive human hematopoietic cells. Proc. Nat'l. Acad. Sci. 95(22):13006–13011.<br>and J.A. Nolta (2002) Molecular mechanism of transforming growth factor beta-mediated cell-<br>ion in primary human CD34(+) progenitors. Blood 99(2):499–506.<br>ge-Griebenow, H.T. Stuwe, O. Cromwell, and H. Fiebig (2000) T cell reactivity with allergoids:<br>te type of APC. J. Immunol. 165(4):1807–1815. |         |         |         |  |
|                                   | Karlsson, J.O., M.L. Yarmush, and M. Toner (1998) Interaction between heat shock and interleukin 6 stimulation in the acute-phase response of human hepatoma (HepG2) cells. Hepatology 28(4):994–1004.   |  |         |         |         |  |

| <b>References,</b><br>Continued: | Lin, M.S., S.J. Swartz, A. Lopez, X. Ding, M.A. Fernandez-Vine, P. Stastny, J.A. Fairley, and L.A. Diaz (1997)<br>Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris.<br>J. Clin. Invest. 99(1):31–40.  |  |  |  |
|----------------------------------|--|--|--|--|
|                                  | Modur, V., G.A. Zimmerman, S.M. Prescott, and T.M. McIntyre (1996) Endothelial cell inflammatory responses to tumor necrosis factor alpha. Ceramide-dependent and -independent mitogen-activated protein kinase cascades. J. Biol. Chem. 271(22):13094–13102.  |  |  |  |
|                                  | Modur, V., Y. Li, G.A. Zimmerman, S.M. Prescott, and T.M. McIntyre (1997) Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. J. Clin. Invest. 100(11):2752–2756.   |  |  |  |
|                                  | Rajan, R., R. Vanderslice, S. Kapur, J. Lynch, R. Thompson, and D. Djakiew (1996) Epidermal growth factor (EGF) promotes chemomigration of a human prostate tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullary bone. Prostate 28(1):1–9. |  |  |  |
|                                  | Wagers, A.J. and G.S. Kansas (2000) Potent induction of alpha(1,3) fucosyltransferase VII in activated CD4 (+) T<br>cells by TGF-beta 1 through a p38 mitogen-activated protein kinase-dependent pathway. J. Immunol.<br>165(9):5011–5016.   |  |  |  |
|                                  | Wang, B.N., E. Kraig, and D. Kolodrubetz (2000) Use of defined mutants to assess the role of the Campylobacter rectus S-layer in bacterium-epithelial cell interactions. Infection and Immunity 68(3):1465–1473.   |  |  |  |
|                                  | Zaitseva, M., S. Lee, C. Lapham, R. Taffs, L. King, T. Romantseva, J. Manischewitz, and H. Golding (2000)<br>Interferon gamma and interleukin 6 modulate the susceptibility of macrophages to human immunodeficiency<br>virus type 1 infection. Blood 96(9):3109–3117.   |  |  |  |

## **Explanation of Symbols**

The symbols present on the product label are explained below:

| Symbol     | Description   | Symbol      | Description                                  |
|------------|---|-------------|--|
| REF        | Catalog Number  | LOT         | Batch code                                   |
| RUO        | Research Use Only   | IVD         | In vitro diagnostic medical device           |
| $\Sigma$   | Use by  | X           | Temperature limitation                       |
|            | Manufacturer  | EC REP      | European Community authorized representative |
| [-]        | Without, does not contain   | [+]         | With, contains                               |
| from Light | Protect from light  | $\triangle$ | Consult accompanying documents               |
| ĺ          | Directs the user to consult instructions for use (IFU), accompanying the product. |             |  |

## Limited Use Label License: Research Use Only

The purchase of this product conveys to the purchaser the limited, non-transferable right to use the purchased amount of the product only to perform internal research for the sole benefit of the purchaser. No right to resell this product or any of its components is conveyed expressly, by implication, or by estoppel. This product is for internal research purposes only and is not for use in commercial applications of any kind, including, without limitation, quality control and commercial services such as reporting the results of purchaser's activities for a fee or other form of consideration. For information on obtaining additional rights, please contact <u>outlicensing@lifetech.com</u> or Out Licensing, Life Technologies, 5791 Van Allen Way, Carlsbad, California 92008.

For Research Use Only. Caution: Not for human or animal therapeutic or diagnostic use. Manufactured under ISO 13485 Quality Standard Manufacturing site: 7335 Executive Way | Frederick, MD 21704 | Toll Free in USA 800.955.6288

© 2011 Life Technologies Corporation. All rights reserved. The trademarks mentioned herein are the property of Life Technologies Corporation or their respective owners.

For support visit www.lifetechnologies.com/support or email techsupport@lifetech.com



www.lifetechnologies.com